Skip to main content
Erschienen in: Current Rheumatology Reports 12/2023

30.09.2023

A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management

verfasst von: Carly Conran, Jason Kolfenbach, Kristine Kuhn, Christopher Striebich, Larry Moreland

Erschienen in: Current Rheumatology Reports | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

A subset of patients with rheumatoid arthritis (RA) who fail multiple biologic therapies are deemed to have “difficult-to-treat” (D2T) RA. In 2021, a European Alliance of Associations for Rheumatology (EULAR) task force proposed a clinical definition of D2T RA. Here we review RA phenotypes and clinical assessment of RA, propose a different definition of D2T RA, discuss possible D2T RA risk factors, and summarize existing literature on the management of D2T RA.

Recent Findings

High disease activity at the time of diagnosis or prior to treatment with a biologic is associated with the development of D2T RA. Prolonged time from diagnosis to beginning treatment has been consistently associated with the development of D2T RA. Other clinical factors such as burden of disease, extraarticular disease, obesity, smoking, pain, fatigue, and psychological conditions have inconsistent associations with D2T RA according to current literature.

Summary

D2T RA is a relatively new concept that represents an area of great need for research regarding the characterization of those with the disease as well as how best to treat the disease. With this gained knowledge, rheumatologists will be able to better identify patients at the time of diagnosis that are likely to develop D2T RA to help guide management.
Literatur
1.
Zurück zum Zitat Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924–39.PubMedCrossRef Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924–39.PubMedCrossRef
2.
Zurück zum Zitat Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.PubMedCrossRef Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.PubMedCrossRef
3.
Zurück zum Zitat Felson DT, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573–86.PubMedPubMedCentralCrossRef Felson DT, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573–86.PubMedPubMedCentralCrossRef
4.
5.
Zurück zum Zitat Kearsley-Fleet L, et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2018;77(10):1405–12.PubMedCrossRef Kearsley-Fleet L, et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2018;77(10):1405–12.PubMedCrossRef
6.
Zurück zum Zitat O’Reilly TJ. Azathioprine in the treatment of refractory rheumatoid arthritis. Ir Med J. 1977;70(11):344–6.PubMed O’Reilly TJ. Azathioprine in the treatment of refractory rheumatoid arthritis. Ir Med J. 1977;70(11):344–6.PubMed
7.
Zurück zum Zitat de Bosset PL, Biter T. Near-cytotoxic gold salt therapy in long standing drug-refractory rheumatoid arthritis. A prospective investigation. Schweiz Med Wochenschr. 1973;103(33):1153–8.PubMed de Bosset PL, Biter T. Near-cytotoxic gold salt therapy in long standing drug-refractory rheumatoid arthritis. A prospective investigation. Schweiz Med Wochenschr. 1973;103(33):1153–8.PubMed
8.
9.
Zurück zum Zitat • Nagy G, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31–5. This is the first consensus on a definition for D2T RA, which is an important step forward for future study of this unique disease subset.PubMedCrossRef • Nagy G, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31–5. This is the first consensus on a definition for D2T RA, which is an important step forward for future study of this unique disease subset.PubMedCrossRef
10.
Zurück zum Zitat de Hair MJH, et al. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2018;57(7):1135–44.PubMed de Hair MJH, et al. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2018;57(7):1135–44.PubMed
11.
Zurück zum Zitat Roodenrijs NMT, et al. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open. 2021;7(1):e001512.PubMedPubMedCentralCrossRef Roodenrijs NMT, et al. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open. 2021;7(1):e001512.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Roodenrijs NMT, et al. Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open. 2021;7(1):e001511.PubMedPubMedCentralCrossRef Roodenrijs NMT, et al. Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open. 2021;7(1):e001511.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Roodenrijs NMT, et al. Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. Rheumatology (Oxford). 2021;60(11):5105–16.PubMedCrossRef Roodenrijs NMT, et al. Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. Rheumatology (Oxford). 2021;60(11):5105–16.PubMedCrossRef
14.
Zurück zum Zitat • Roodenrijs NMT, et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology (Oxford). 2022;61(9):3552–66. This comprehensive review of possible immune mechanisms driving the development of D2T RA addresses the complexity of this syndrome.PubMedCrossRef • Roodenrijs NMT, et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology (Oxford). 2022;61(9):3552–66. This comprehensive review of possible immune mechanisms driving the development of D2T RA addresses the complexity of this syndrome.PubMedCrossRef
15.
Zurück zum Zitat Ochi S, et al. Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. Clin Exp Rheumatol. 2022;40(1):86–96.PubMedCrossRef Ochi S, et al. Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. Clin Exp Rheumatol. 2022;40(1):86–96.PubMedCrossRef
17.
Zurück zum Zitat Messelink MA, et al. Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon. Arthritis Res Ther. 2021;23(1):184.PubMedPubMedCentralCrossRef Messelink MA, et al. Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon. Arthritis Res Ther. 2021;23(1):184.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat • Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(1):17–33. The authors have identified key similarities and differences between those with RA who have persistent symptoms, but who have and do not have objective evidence of ongoing inflammatory disease activity. This clearly represents a key clinical challenge and an area in need of future research focus.PubMedCrossRef • Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(1):17–33. The authors have identified key similarities and differences between those with RA who have persistent symptoms, but who have and do not have objective evidence of ongoing inflammatory disease activity. This clearly represents a key clinical challenge and an area in need of future research focus.PubMedCrossRef
19.
Zurück zum Zitat Becede M, et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum. 2019;49(2):211–7.PubMedCrossRef Becede M, et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum. 2019;49(2):211–7.PubMedCrossRef
21.
Zurück zum Zitat Watanabe R, et al. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunol Med. 2022;45(1):35–44.PubMedCrossRef Watanabe R, et al. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunol Med. 2022;45(1):35–44.PubMedCrossRef
22.
Zurück zum Zitat Takanashi S, Kaneko Y, Takeuchi T. Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021;60(11):5247–56.PubMedCrossRef Takanashi S, Kaneko Y, Takeuchi T. Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021;60(11):5247–56.PubMedCrossRef
23.
Zurück zum Zitat Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res Ther. 2017;19(1):68.PubMedPubMedCentralCrossRef Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res Ther. 2017;19(1):68.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Anderson J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64(5):640–7.PubMedCrossRef Anderson J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64(5):640–7.PubMedCrossRef
25.
Zurück zum Zitat England BR, et al. 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis Care Res (Hoboken). 2019;71(12):1540–55.PubMedCrossRef England BR, et al. 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis Care Res (Hoboken). 2019;71(12):1540–55.PubMedCrossRef
26.
Zurück zum Zitat Lee YC, et al. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Ann Rheum Dis. 2013;72(6):949–54.PubMedCrossRef Lee YC, et al. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Ann Rheum Dis. 2013;72(6):949–54.PubMedCrossRef
27.
Zurück zum Zitat Joharatnam N, et al. A cross-sectional study of pain sensitivity, disease-activity assessment, mental health, and fibromyalgia status in rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):11.PubMedPubMedCentralCrossRef Joharatnam N, et al. A cross-sectional study of pain sensitivity, disease-activity assessment, mental health, and fibromyalgia status in rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):11.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Ton E, et al. Look beyond the disease activity score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis. J Rheumatol. 2012;39(1):22–7.PubMedCrossRef Ton E, et al. Look beyond the disease activity score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis. J Rheumatol. 2012;39(1):22–7.PubMedCrossRef
29.
Zurück zum Zitat Ferreira RJO, et al. Suppressing inflammation in rheumatoid arthritis: does patient global assessment blur the target? A practice-based call for a paradigm change. Arthritis Care Res (Hoboken). 2018;70(3):369–78.PubMedCrossRef Ferreira RJO, et al. Suppressing inflammation in rheumatoid arthritis: does patient global assessment blur the target? A practice-based call for a paradigm change. Arthritis Care Res (Hoboken). 2018;70(3):369–78.PubMedCrossRef
30.
Zurück zum Zitat Holdsworth EA, et al. Biologic and targeted synthetic DMARD utilization in the United States: Adelphi Real World disease specific programme for rheumatoid arthritis. Rheumatol Ther. 2021;8(4):1637–49.PubMedPubMedCentralCrossRef Holdsworth EA, et al. Biologic and targeted synthetic DMARD utilization in the United States: Adelphi Real World disease specific programme for rheumatoid arthritis. Rheumatol Ther. 2021;8(4):1637–49.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Backhaus M, et al. Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum. 1999;42(6):1232–45.PubMedCrossRef Backhaus M, et al. Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum. 1999;42(6):1232–45.PubMedCrossRef
32.
Zurück zum Zitat Dougados M, et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis. 2013;72(5):665–71.PubMedCrossRef Dougados M, et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis. 2013;72(5):665–71.PubMedCrossRef
33.
Zurück zum Zitat Kane D, Balint PV, Sturrock RD. Ultrasonography is superior to clinical examination in the detection and localization of knee joint effusion in rheumatoid arthritis. J Rheumatol. 2003;30(5):966–71.PubMed Kane D, Balint PV, Sturrock RD. Ultrasonography is superior to clinical examination in the detection and localization of knee joint effusion in rheumatoid arthritis. J Rheumatol. 2003;30(5):966–71.PubMed
34.
Zurück zum Zitat Moller-Bisgaard S, et al. Effect of magnetic resonance imaging vs conventional treat-to-target strategies on disease activity remission and radiographic progression in rheumatoid arthritis: The IMAGINE-RA randomized clinical trial. JAMA. 2019;321(5):461–72.PubMedPubMedCentralCrossRef Moller-Bisgaard S, et al. Effect of magnetic resonance imaging vs conventional treat-to-target strategies on disease activity remission and radiographic progression in rheumatoid arthritis: The IMAGINE-RA randomized clinical trial. JAMA. 2019;321(5):461–72.PubMedPubMedCentralCrossRef
35.
36.
Zurück zum Zitat Roodenrijs NMT, et al. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis. 2018;77(12):1705–9.PubMedCrossRef Roodenrijs NMT, et al. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis. 2018;77(12):1705–9.PubMedCrossRef
37.
38.
Zurück zum Zitat Khader Y, et al. Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. Clin Rheumatol. 2022;41(12):3615–27.PubMedPubMedCentralCrossRef Khader Y, et al. Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. Clin Rheumatol. 2022;41(12):3615–27.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Giollo A, et al. Early characterisation of difficult-to-treat rheumatoid arthritis by suboptimal initial management A multicentre cohort study. Rheumatology (Oxford). 2022;62:2083–9.CrossRef Giollo A, et al. Early characterisation of difficult-to-treat rheumatoid arthritis by suboptimal initial management A multicentre cohort study. Rheumatology (Oxford). 2022;62:2083–9.CrossRef
40.
41.
Zurück zum Zitat Gardette A, et al. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine. 2014;81(5):416–20.PubMedCrossRef Gardette A, et al. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine. 2014;81(5):416–20.PubMedCrossRef
42.
Zurück zum Zitat Harrold LR, et al. Association between baseline anti-cyclic Citrullinated peptide antibodies and 6-Month clinical response following Abatacept or TNF inhibitor treatment: a real-world analysis of biologic-experienced patients with RA. Rheumatol Ther. 2021;8(2):937–53.PubMedPubMedCentralCrossRef Harrold LR, et al. Association between baseline anti-cyclic Citrullinated peptide antibodies and 6-Month clinical response following Abatacept or TNF inhibitor treatment: a real-world analysis of biologic-experienced patients with RA. Rheumatol Ther. 2021;8(2):937–53.PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Cojocaru M, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Bucur). 2010;5(4):286–91.PubMed Cojocaru M, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Bucur). 2010;5(4):286–91.PubMed
44.
Zurück zum Zitat Roodenrijs NMT, et al. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology (Oxford). 2021;60(8):3778–88.PubMedCrossRef Roodenrijs NMT, et al. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology (Oxford). 2021;60(8):3778–88.PubMedCrossRef
45.
Zurück zum Zitat Dey M, Nagy G, Nikiphorou E. Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin? Rheumatology (Oxford). 2022;62:1773–9.CrossRef Dey M, Nagy G, Nikiphorou E. Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin? Rheumatology (Oxford). 2022;62:1773–9.CrossRef
46.
Zurück zum Zitat Deane KD, Holers VM. Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift. Arthritis Rheumatol. 2021;73(2):181–93.PubMedCrossRef Deane KD, Holers VM. Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift. Arthritis Rheumatol. 2021;73(2):181–93.PubMedCrossRef
47.
Zurück zum Zitat Moroni L, Farina N, Dagna L. Obesity and its role in the management of rheumatoid and psoriatic arthritis. Clin Rheumatol. 2020;39(4):1039–47.PubMedCrossRef Moroni L, Farina N, Dagna L. Obesity and its role in the management of rheumatoid and psoriatic arthritis. Clin Rheumatol. 2020;39(4):1039–47.PubMedCrossRef
48.
Zurück zum Zitat Klaasen R, et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 2011;63(2):359–64.PubMedCrossRef Klaasen R, et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 2011;63(2):359–64.PubMedCrossRef
50.
Zurück zum Zitat Nii T, et al. Crosstalk between tumor necrosis factor-alpha signaling and aryl hydrocarbon receptor signaling in nuclear factor -kappa B activation: A possible molecular mechanism underlying the reduced efficacy of TNF-inhibitors in rheumatoid arthritis by smoking. J Autoimmun. 2019;98:95–102.PubMedCrossRef Nii T, et al. Crosstalk between tumor necrosis factor-alpha signaling and aryl hydrocarbon receptor signaling in nuclear factor -kappa B activation: A possible molecular mechanism underlying the reduced efficacy of TNF-inhibitors in rheumatoid arthritis by smoking. J Autoimmun. 2019;98:95–102.PubMedCrossRef
51.
Zurück zum Zitat Goebel A, et al. The autoimmune aetiology of unexplained chronic pain. Autoimmun Rev. 2022;21(3):103015.PubMedCrossRef Goebel A, et al. The autoimmune aetiology of unexplained chronic pain. Autoimmun Rev. 2022;21(3):103015.PubMedCrossRef
53.
Zurück zum Zitat Wallace BI, et al. Fibromyalgianess and glucocorticoid persistence among patients with rheumatoid arthritis. Rheumatology (Oxford). 2022;61(4):1556–62.PubMedCrossRef Wallace BI, et al. Fibromyalgianess and glucocorticoid persistence among patients with rheumatoid arthritis. Rheumatology (Oxford). 2022;61(4):1556–62.PubMedCrossRef
54.
Zurück zum Zitat Nerurkar L, et al. Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry. 2019;6(2):164–73.PubMedCrossRef Nerurkar L, et al. Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry. 2019;6(2):164–73.PubMedCrossRef
55.
Zurück zum Zitat Figus FA, et al. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev. 2021;20(4):102776.PubMedCrossRef Figus FA, et al. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev. 2021;20(4):102776.PubMedCrossRef
56.
57.
Zurück zum Zitat Sokka T, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009;11(1):R7.PubMedPubMedCentral Sokka T, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009;11(1):R7.PubMedPubMedCentral
58.
Zurück zum Zitat Intriago M, et al. Clinical characteristics in patients with rheumatoid arthritis: differences between genders. ScientificWorldJournal. 2019;2019:8103812.PubMedPubMedCentralCrossRef Intriago M, et al. Clinical characteristics in patients with rheumatoid arthritis: differences between genders. ScientificWorldJournal. 2019;2019:8103812.PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Lechtenboehmer CA, et al. Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis. Arthritis Res Ther. 2021;23(1):267.PubMedPubMedCentralCrossRef Lechtenboehmer CA, et al. Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis. Arthritis Res Ther. 2021;23(1):267.PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Aletaha D, et al. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(12):1609–15.PubMedCrossRef Aletaha D, et al. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(12):1609–15.PubMedCrossRef
62.
Zurück zum Zitat Ochi S, et al. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther. 2022;24(1):61.PubMedPubMedCentralCrossRef Ochi S, et al. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther. 2022;24(1):61.PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Thomas SS, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015;29(4):241–58.PubMedCrossRef Thomas SS, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015;29(4):241–58.PubMedCrossRef
64.
Zurück zum Zitat Krintel SB, et al. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology (Oxford). 2013;52(7):1245–53.PubMedCrossRef Krintel SB, et al. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology (Oxford). 2013;52(7):1245–53.PubMedCrossRef
65.
66.
Zurück zum Zitat England BR, et al. 2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis. Arthritis Rheumatol, 2023. England BR, et al. 2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis. Arthritis Rheumatol, 2023.
67.
Zurück zum Zitat Constien D, Davidson E, Phillips LR. Patient perspectives on the 2022 American College of rheumatology guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023;75(8):1616–7. https://doi.org/10.1002/acr.25124.CrossRefPubMed Constien D, Davidson E, Phillips LR. Patient perspectives on the 2022 American College of rheumatology guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023;75(8):1616–7. https://​doi.​org/​10.​1002/​acr.​25124.CrossRefPubMed
68.
Zurück zum Zitat Baker NA, et al. Occupational therapy is a vital member of the interprofessional team-based approach for the management of rheumatoid arthritis: applying the 2022 American College of rheumatology guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023;75(8):1618–24. https://doi.org/10.1002/acr.25122.CrossRefPubMed Baker NA, et al. Occupational therapy is a vital member of the interprofessional team-based approach for the management of rheumatoid arthritis: applying the 2022 American College of rheumatology guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023;75(8):1618–24. https://​doi.​org/​10.​1002/​acr.​25122.CrossRefPubMed
Metadaten
Titel
A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management
verfasst von
Carly Conran
Jason Kolfenbach
Kristine Kuhn
Christopher Striebich
Larry Moreland
Publikationsdatum
30.09.2023
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 12/2023
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-023-01117-6

Weitere Artikel der Ausgabe 12/2023

Current Rheumatology Reports 12/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.